MDM4 and neoplasm: Finally, inhibitors that simultaneously interfere with the action of Mdm2 and its heterodimerization partner MdmX/Mdm4 were recently published [56], again showing a broader activity against tumor cells, and may thus warrant combination strategies with Wip1i.